$2.17
-0.01[-0.46%]
At close: Apr 25
$2.17
0[0.00%]
PreMarket: 7:06AM EDT
Emergent BioSolutions
(NYSE:EBS)Emergent BioSolutions Stock (NYSE:EBS), Analyst Ratings, Price Targets, Predictions
Emergent BioSolutions Inc has a consensus price target of $21.17, established from looking at the 18 latest analyst ratings. The last 3 analyst ratings were released from Benchmark, Benchmark, and JP Morgan on April 11, 2024, March 7, 2024, and November 20, 2023. With an average price target of $3.33 between Benchmark, Benchmark, and JP Morgan, there's an implied 53.61% upside for Emergent BioSolutions Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Benchmark
JP Morgan
Chardan Capital
Cowen & Co.
Wells Fargo
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Emergent BioSolutions
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/11/2024 | EBS | Buy Now | Emergent BioSolutions | $2.17 | 130.41% | Benchmark | Robert Wasserman | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | EBS | Buy Now | Emergent BioSolutions | $2.17 | 130.41% | Benchmark | Robert Wasserman | → $5 | Upgrade | Hold → Buy | Get Alert |
| 11/20/2023 | EBS | Buy Now | Emergent BioSolutions | $2.17 | — | JP Morgan | Jessica Fye | — | Reinstates | → Underweight | Get Alert |
| 08/29/2023 | EBS | Buy Now | Emergent BioSolutions | $2.17 | — | Benchmark | Robert Wasserman | — | Downgrade | Buy → Hold | Get Alert |
| 05/31/2023 | EBS | Buy Now | Emergent BioSolutions | $2.17 | 913.82% | Benchmark | Robert Wasserman | → $22 | Reiterates | Buy → Buy | Get Alert |
| 05/19/2023 | EBS | Buy Now | Emergent BioSolutions | $2.17 | 913.82% | Benchmark | Robert Wasserman | → $22 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2023 | EBS | Buy Now | Emergent BioSolutions | $2.17 | 913.82% | Benchmark | Robert Wasserman | → $22 | Upgrade | Hold → Buy | Get Alert |
| 03/17/2023 | EBS | Buy Now | Emergent BioSolutions | $2.17 | 314.75% | JP Morgan | Jessica Fye | $23 → $9 | Downgrade | Neutral → Underweight | Get Alert |
| 11/10/2022 | EBS | Buy Now | Emergent BioSolutions | $2.17 | — | Benchmark | Robert Wasserman | — | Downgrade | Buy → Hold | Get Alert |
| 11/09/2022 | EBS | Buy Now | Emergent BioSolutions | $2.17 | 2434.56% | Chardan Capital | Keay Nakae | $65 → $55 | Maintains | Buy | Get Alert |
| 09/12/2022 | EBS | Buy Now | Emergent BioSolutions | $2.17 | 1236.41% | Cowen & Co. | Boris Peaker | $30 → $29 | Maintains | Market Perform | Get Alert |
| 05/04/2022 | EBS | Buy Now | Emergent BioSolutions | $2.17 | 1651.15% | Wells Fargo | Jacob Hughes | $46 → $38 | Maintains | Equal-Weight | Get Alert |
| 04/29/2022 | EBS | Buy Now | Emergent BioSolutions | $2.17 | 2895.39% | Chardan Capital | Keay Nakae | $75 → $65 | Maintains | Buy | Get Alert |
| 03/10/2022 | EBS | Buy Now | Emergent BioSolutions | $2.17 | 1743.32% | Wells Fargo | Jacob Hughes | $37 → $40 | Maintains | Equal-Weight | Get Alert |
| 11/10/2021 | EBS | Buy Now | Emergent BioSolutions | $2.17 | 3356.22% | Chardan Capital | Keay Nakae | — | Maintains | Buy | Get Alert |
| 11/08/2021 | EBS | Buy Now | Emergent BioSolutions | $2.17 | — | Benchmark | Robert Wasserman | — | Downgrade | Buy → Hold | Get Alert |
| 05/05/2021 | EBS | Buy Now | Emergent BioSolutions | $2.17 | — | Argus Research | Jasper Hellweg | — | Downgrade | Buy → Hold | Get Alert |
| 04/30/2021 | EBS | Buy Now | Emergent BioSolutions | $2.17 | 4139.63% | Chardan Capital | Keay Nakae | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Emergent BioSolutions (EBS)?
The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by Benchmark on April 11, 2024. The analyst firm set a price target for $5.00 expecting EBS to rise to within 12 months (a possible 130.41% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Emergent BioSolutions (EBS)?
The latest analyst rating for Emergent BioSolutions (NYSE: EBS) was provided by Benchmark, and Emergent BioSolutions reiterated their buy rating.
When was the last upgrade for Emergent BioSolutions (EBS)?
The last upgrade for Emergent BioSolutions Inc happened on March 7, 2024 when Benchmark raised their price target to $5. Benchmark previously had a hold for Emergent BioSolutions Inc.
When was the last downgrade for Emergent BioSolutions (EBS)?
The last downgrade for Emergent BioSolutions Inc happened on August 29, 2023 when Benchmark changed their price target from N/A to N/A for Emergent BioSolutions Inc.
When is the next analyst rating going to be posted or updated for Emergent BioSolutions (EBS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Emergent BioSolutions, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Emergent BioSolutions was filed on April 11, 2024 so you should expect the next rating to be made available sometime around April 11, 2025.
Is the Analyst Rating Emergent BioSolutions (EBS) correct?
While ratings are subjective and will change, the latest Emergent BioSolutions (EBS) rating was a reiterated with a price target of $0.00 to $5.00. The current price Emergent BioSolutions (EBS) is trading at is $2.17, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.